拓扑替康联合顺铂治疗小细胞肺癌疗效观察

Effect of combined chemotherapy of topotecan and cisplatin in treatment of small-cell lung cancer

目的:探讨拓扑替康(topotecan,TPT)联合顺铂(DDP)治疗小细胞肺癌(smallcelllungcancer,SCLC)的疗效。方法:35例初治SCLC患者应用TPT1mg/(m2·d),静脉滴入30min;联合DDP20mg/(m2·d),静脉滴入,连用5d,每3周为1个周期,2～3个周期后评价疗效和不良反应。结果:TPT与DDP联合用于初治SCLC有效率为74.3%(26/35),其中CR20.0%(7/35),PR54.3%(19/35)。主要不良反应为骨髓抑制,其中Ⅲ～Ⅳ度中性粒细胞缺乏为54.3%(19/35),Ⅲ～Ⅳ度血小板下降为34.3%(12/35),Ⅲ～Ⅳ度血红蛋白下降为20.0%(7/35),非血液学毒性较轻。结论:TPT联合DDP是治疗SCLC疗效较好方案,主要不良反应为血液学毒性。

OBJECTIVE： To investigate the efficacy and toxicity of topotecan plus cisplatin in the treatment of small-cell lung cancer （SCLC）. METHODS： Thirty-five previously untreated patients with SCI.C received the combined chemotherapy of topotecan and cisplatin, topotecan 1 mg/（m^2 · d）, iv infusion for 5 days; cisplatin 20 mg/（m^2 · d）, iv infusion for 5 days, reapeated every 21 days. Assessment was given after 2 or 3 cycles. RESULTS： CR was in 7 cases （20.0%）,PR 19 cases（54.3%）, and the overall response rate was 74.3%（26/ 35）. The main side effect was myelosuppression, and Grade Ⅲ-Ⅳ neutropenia , thrombopenia and anemia were 54.3 % （ 19/ 35）, 34.3% （12/35）, 20.0% （7/35） respectively. CONCLUSIONS：Topotecan plus cisplatin is a better regimen for the treatment of SCLC, and the main toxicity of this regimen is hematological toxicity.